490 related articles for article (PubMed ID: 33919732)
1. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
Lakshmanachetty S; Cruz-Cruz J; Hoffmeyer E; Cole AP; Mitra SS
Cells; 2021 Apr; 10(4):. PubMed ID: 33919732
[TBL] [Abstract][Full Text] [Related]
2. The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment.
Mi Y; Guo N; Luan J; Cheng J; Hu Z; Jiang P; Jin W; Gao X
Front Immunol; 2020; 11():737. PubMed ID: 32391020
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Bossman SA; Ter Laan M; Wesseling P; Adema GJ
Neuro Oncol; 2016 Sep; 18(9):1253-64. PubMed ID: 27006175
[TBL] [Abstract][Full Text] [Related]
4. Functional assay to assess T-cell inhibitory properties of myeloid derived suppressor cells (MDSCs) isolated from the tumor microenvironment of murine glioma models.
Alghamri MS; Kamran N; Kadiyala P; Lowenstein PR; Castro MG
Methods Enzymol; 2020; 632():215-228. PubMed ID: 32000897
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
[TBL] [Abstract][Full Text] [Related]
6. High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T
Löhr M; Freitag B; Technau A; Krauss J; Monoranu CM; Rachor J; Lutz MB; Hagemann C; Kessler AF; Linsenmann T; Wölfl M; Ernestus RI; Engelhardt S; Gelbrich G; Schlegel PG; Eyrich M
Cancer Immunol Immunother; 2018 Oct; 67(10):1545-1558. PubMed ID: 30054667
[TBL] [Abstract][Full Text] [Related]
7. Immune microenvironment of gliomas.
Gieryng A; Pszczolkowska D; Walentynowicz KA; Rajan WD; Kaminska B
Lab Invest; 2017 May; 97(5):498-518. PubMed ID: 28287634
[TBL] [Abstract][Full Text] [Related]
8. Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2
Takacs GP; Kreiger CJ; Luo D; Tian G; Garcia JS; Deleyrolle LP; Mitchell DA; Harrison JK
Front Immunol; 2022; 13():993444. PubMed ID: 36685592
[TBL] [Abstract][Full Text] [Related]
9. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells.
Chang AL; Miska J; Wainwright DA; Dey M; Rivetta CV; Yu D; Kanojia D; Pituch KC; Qiao J; Pytel P; Han Y; Wu M; Zhang L; Horbinski CM; Ahmed AU; Lesniak MS
Cancer Res; 2016 Oct; 76(19):5671-5682. PubMed ID: 27530322
[TBL] [Abstract][Full Text] [Related]
10. Role of myeloid cells in the immunosuppressive microenvironment in gliomas.
Locarno CV; Simonelli M; Carenza C; Capucetti A; Stanzani E; Lorenzi E; Persico P; Della Bella S; Passoni L; Mavilio D; Bonecchi R; Locati M; Savino B
Immunobiology; 2020 Jan; 225(1):151853. PubMed ID: 31703822
[TBL] [Abstract][Full Text] [Related]
11. Glioma exosomes mediate the expansion and function of myeloid-derived suppressor cells through microRNA-29a/Hbp1 and microRNA-92a/Prkar1a pathways.
Guo X; Qiu W; Wang J; Liu Q; Qian M; Wang S; Zhang Z; Gao X; Chen Z; Guo Q; Xu J; Xue H; Li G
Int J Cancer; 2019 Jun; 144(12):3111-3126. PubMed ID: 30536597
[TBL] [Abstract][Full Text] [Related]
12. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.
Santegoets KCM; Gielen PR; Büll C; Schulte BM; Kers-Rebel ED; Küsters B; Bossman SAJFH; Ter Laan M; Wesseling P; Adema GJ
Cancer Immunol Immunother; 2019 Jun; 68(6):937-949. PubMed ID: 30953118
[TBL] [Abstract][Full Text] [Related]
13. Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma.
Richard SA
Dis Markers; 2020; 2020():8844313. PubMed ID: 33204365
[TBL] [Abstract][Full Text] [Related]
14. Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma.
Won WJ; Deshane JS; Leavenworth JW; Oliva CR; Griguer CE
Cell Stress; 2019 Jan; 3(2):47-65. PubMed ID: 31225500
[TBL] [Abstract][Full Text] [Related]
15. The Role of Myeloid Cells in GBM Immunosuppression.
Lin YJ; Wu CY; Wu JY; Lim M
Front Immunol; 2022; 13():887781. PubMed ID: 35711434
[TBL] [Abstract][Full Text] [Related]
16. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond.
Zhao Y; Du J; Shen X
Front Immunol; 2023; 14():1157537. PubMed ID: 37006306
[TBL] [Abstract][Full Text] [Related]
17. Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression.
Alban TJ; Bayik D; Otvos B; Rabljenovic A; Leng L; Jia-Shiun L; Roversi G; Lauko A; Momin AA; Mohammadi AM; Peereboom DM; Ahluwalia MS; Matsuda K; Yun K; Bucala R; Vogelbaum MA; Lathia JD
Front Immunol; 2020; 11():1191. PubMed ID: 32625208
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
Front Immunol; 2020; 11():585214. PubMed ID: 33613512
[TBL] [Abstract][Full Text] [Related]
19. A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment.
Hofer F; Di Sario G; Musiu C; Sartoris S; De Sanctis F; Ugel S
Cells; 2021 Oct; 10(10):. PubMed ID: 34685679
[TBL] [Abstract][Full Text] [Related]
20. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
